Novo Nordisk stated Tuesday it was tapping Maziar Mike Doustdar, its head of worldwide operations, as its new CEO.
Novo’s present CEO, Lars Fruergaard Jørgensen, introduced he was stepping down in Might, as the corporate confronted a tumbling share worth and rising competitors from Eli Lilly within the weight problems market. Doustdar will begin as CEO on Aug. 7, Novo stated.
He assumes the function as Novo struggles to change into extra aggressive once more. The drugmaker on Tuesday additionally minimize its 2025 development outlook, saying it now expects gross sales to develop from 8% to 14% and revenue to develop from 10% to 16%, whereas its earlier outlook was 13% to 21% and 16% to 24%, respectively.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
